Key Developments: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

4 Sep 2015
Change (% chg)

$-0.03 (-1.50%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sequenom changes in registrant’s certifying accountant - Form 8-K
Thursday, 25 Jun 2015 06:02am EDT 

Sequenom:On June 19, Company notified Ernst & Young LLP of its dismissal as the Company’s independent registered public accounting firm effective as of that date.On June 19, Company selected KPMG LLP as its new independent registered public accounting firm.  Full Article

Sequenom Inc's Sequenom Laboratories launches the HerediT UNIVERSAL Test in collaboration with Recombine
Thursday, 19 Mar 2015 05:30pm EDT 

Sequenom Laboratories:Says the launch of the HerediT UNIVERSAL carrier screening test as a service to ordering physicians.Launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.Current options are limited to single gene testing or tests that can identify about 100 hereditary conditions.This new offering can be performed preconception or at any time during pregnancy.Sequenom Laboratories is a wholly owned subsidiary of Sequenom Inc.  Full Article

Kenneth Buechler elected Chairman of Sequenom Inc Board of Directors
Tuesday, 17 Mar 2015 07:00am EDT 

Sequenom Inc:Board elected Kenneth Buechler as Chairman of Board, effective April 1.Says Buechler succeeds Harry Hixson, Jr. who will retire from position effective March 31, after 11 years of service.  Full Article

Sequenom Inc and Cypher Genomics Inc announce development agreement
Thursday, 22 Jan 2015 07:00am EST 

Sequenom Inc and Cypher Genomics Inc:Say a development agreement for next generation noninvasive prenatal tests (NIPT).Through this agreement, Sequenom will utilize Cypher's genome interpretation technology, called Mantis, to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood.Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with risks of morbidity and mortality.  Full Article

Sequenom purchases noninvasive prenatal testing intellectual property from Isis Innovation
Monday, 6 Oct 2014 04:30pm EDT 

Sequenom Inc:Says the company and Isis Innovation Ltd jointly announced that Sequenom has purchased noninvasive prenatal testing intellectual property from Isis Innovation, for $14.55 mln.Under the terms of the agreement, Sequenom is now the owner of global intellectual property for noninvasive prenatal genetic diagnostic testing on paternally inherited fetal nucleic acids derived from maternal plasma or serum.Purchase price includes $3.2 mln as the final royalty payment due to Isis under the prior agreement and the waiver of $2.1 million in paid legal fees that Isis owed to Sequenom, with additional downstream payments contingent on revenues exceeding certain thresholds.  Full Article

Nicox and Sequenom announces launch of expanded access to RetnaGene test portfolio in the U.S
Thursday, 19 Jun 2014 07:00am EDT 

Sequenom Inc:Nicox and Sequenom announces that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(tm) portfolio of laboratory-developed genetic tests in the United States (U.S.).RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration.  Full Article

Sequenom receives U.S. FDA premarket clearance
Monday, 16 Jun 2014 08:00am EDT 

Sequenom Inc:Receives premarket 510(k) clearance from the United States Food and Drug Administration (FDA) to market its IMPACT Dx Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx System.IMPACT Dx Factor V Leiden and Factor II Genotyping Test is performed on the IMPACT Dx System, and is indicated for use as an aid in the diagnosis of patients with suspected thrombophilia.  Full Article

Sequenom Laboratories and Quest Diagnostics collaborate to expand patient access to the MaterniT21 PLUS Noninvasive Prenatal Test
Monday, 16 Jun 2014 08:00am EDT 

Sequenom Inc and Quest Diagnostics Inc:Announces an agreement under which Quest will offer national access to Sequenom Laboratories' MaterniT21 PLUS laboratory-developed test.Quest expects to begin offering access to the test in the third quarter.Also Quest has formed a license agreement with Sequenom for certain NIPT patents and patent applications.License agreement is the first formed by Sequenom with a commercial lab in the United States.Quest intends to use the intellectual property for the purposes of developing and validating its own lab-developed NIPT test.  Full Article

Sequenom Inc's Sequenom laboratories announces national coverage agreement for prenatal diagnostic testing services
Monday, 9 Jun 2014 07:00am EDT 

Sequenom Inc:Says its wholly owned subsidiary, Sequenom Laboratories signs national agreement with health insurance company covering 13 mln people throughout United States.Says to provide MaterniT21 PLUS laboratory-developed test (LDT).Addition of this contract brings number of covered lives under agreement by Sequenom Laboratories' diagnostic services to more than 140 mln.  Full Article

Sequenom Inc's bioscience business acquired by Agena Bioscience
Friday, 30 May 2014 04:30pm EDT 

Sequenom Inc:Says Agena Bioscience, Inc, a portfolio company of Telegraph Hill Partners (THP) acquired the Bioscience business of the company.Agena Bioscience has retained the employees of the acquired segment and will remain headquartered in San Diego, California.  Full Article

Search Stocks